 |
Journal of scientists, physicists, mathematicians, engineers, inventors, nature, biology, technology, animal kingdoms, and science projects.
Home
ANC News
Animals
Biographies
Biology
Chemistry
Environment
Free Updates
General Science
Headlines
Human Body
Inventors
Kids to 12
Physics
Questions&
Answers
Quantum
Resources
Projects &
Experiments
Science@NASA
Submission
Guideline
Tables
Technology
US Geological Survey
If you have questions concerning this website, contact webmaster@light-science.com
| Carl Sagan's COSMOS is one of the most influential science programs ever made.
Strange Science. Rocky road to biology and paleontology.
Genetic Science Learning Center. Resources for students, teachers, and families.
The Biology Project. Kids corner of interactive lessons with lesson plans by teachers.
College Physics for Students of Biology and Chemistry. Textbook with Java applets.
Biology Online. Dictionary and tutorials online.
|
|
|
Applied Biosystems introduces new chemistries to increase DNA sequencing productivity
by Lori Murray - Applied Biosystems
FOSTER CITY, CA – September 18, 2002 – Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced the launch of two new versions of its BigDye® Terminator Cycle Sequencing Kit, designed to increase productivity and improve data quality for DNA sequencing applications. These enhanced products are a result of Applied Biosystems' goal to improve sequencing technologies for rapid, accurate and cost effective DNA analysis for studying human and other genomes.
BigDye® Terminator v3.1 Cycle Sequencing Kit is designed for the majority of applications, including de novo sequencing and resequencing. The BigDye® Terminator v1.1 Cycle Sequencing Kit is designed for specialty applications, such as sequencing PCR products associated with comparative sequencing when using a rapid instrument run. Together BigDye® Terminator v3.1 and v1.1 kits are expected to meet the requirements of nearly all sequencing applications performed today. These new formulations are designed to provide researchers with improved performance in sequencing difficult templates, resulting in longer read lengths and higher success rates.
A large percentage of the finishing costs for production-scale sequencing projects are associated with sequencing difficult templates. Some initial customer test sites have reported obtaining an additional 50-100 high-quality bases when using the new chemistries. With a greater ability to sequence difficult templates, customers are expected to be able to complete projects in less time and to lower the overall cost of sequencing projects. Each kit is compatible with Applied Biosystems genetic analysis instruments.
"With the tandem release of these two products, Applied Biosystems should be able to meet the needs of our entire customer base, which is engaged in all types of DNA sequencing applications," said Michael W. Hunkapiller, Ph.D., President of Applied Biosystems. "These products enable longer sequencing reads and higher success rates providing greater capability, which could reduce overall project costs. Decreasing the cost of sequencing is a goal we share with our customers, and we believe these new chemistries will move us further along that path."
About Applera Corporation and Applied Biosystems:
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. The Celera Genomics Group (NYSE:CRA), located in Rockville, MD and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its genomic and proteomics technology platforms to identify drug targets and diagnostic marker candidates and to discover novel therapeutics. Its Celera Discovery SystemTM online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at http://www.applera.com/, or by telephoning 800.762.6923. Information about Applied Biosystems is available on the World Wide Web at http://www.appliedbiosystems.com/.
|
|
|
|
|
